Literature DB >> 26432405

PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.

Sofie Mohlin1, Arash Hamidian1, Kristoffer von Stedingk1, Esther Bridges2, Caroline Wigerup1, Daniel Bexell1, Sven Påhlman3.   

Abstract

Hypoxia-inducible factor (HIF) is a master regulator of cellular responses to oxygen deprival with a critical role in mediating the angiogenic switch in solid tumors. Differential expression of the HIF subunits HIF1α and HIF2α occurs in many human tumor types, suggesting selective implications to biologic context. For example, high expression of HIF2α that occurs in neuroblastoma is associated with stem cell-like features, disseminated disease, and poor clinical outcomes, suggesting pivotal significance for HIF2 control in neuroblastoma biology. In this study, we provide novel insights into how HIF2α expression is transcriptionally controlled by hypoxia and how this control is abrogated by inhibition of insulin-like growth factor-1R/INSR-driven phosphoinositide 3-kinase (PI3K) signaling. Reducing PI3K activity was sufficient to decrease HIF2α mRNA and protein expression in a manner with smaller and less vascularized tumors in vivo. PI3K-regulated HIF2A mRNA expression was independent of Akt or mTORC1 signaling but relied upon mTORC2 signaling. HIF2A mRNA was induced by hypoxia in neuroblastoma cells isolated from metastatic patient-derived tumor xenografts, where HIF2A levels could be reduced by treatment with PI3K and mTORC2 inhibitors. Our results suggest that targeting PI3K and mTORC2 in aggressive neuroblastomas with an immature phenotype may improve therapeutic efficacy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26432405     DOI: 10.1158/0008-5472.CAN-15-0708

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.

Authors:  Svenja Nölting; Ashley Grossman; Karel Pacak
Journal:  Exp Clin Endocrinol Diabetes       Date:  2018-09-20       Impact factor: 2.949

Review 2.  The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.

Authors:  Najah Albadari; Shanshan Deng; Wei Li
Journal:  Expert Opin Drug Discov       Date:  2019-05-09       Impact factor: 6.098

3.  Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma.

Authors:  Petra Miikkulainen; Heidi Högel; Fatemeh Seyednasrollah; Krista Rantanen; Laura L Elo; Panu M Jaakkola
Journal:  J Biol Chem       Date:  2019-01-07       Impact factor: 5.157

Review 4.  The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies.

Authors:  Joaquín Araos; Jonathan P Sleeman; Boyan K Garvalov
Journal:  Clin Exp Metastasis       Date:  2018-08-31       Impact factor: 5.150

5.  Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

Authors:  Guillermo de Velasco; Aedín C Culhane; André P Fay; A Ari Hakimi; Martin H Voss; Nizar M Tannir; Pheroze Tamboli; Leonard J Appleman; Joaquim Bellmunt; W Kimryn Rathmell; Laurence Albiges; James J Hsieh; Daniel Y C Heng; Sabina Signoretti; Toni K Choueiri
Journal:  Oncologist       Date:  2017-02-20

6.  MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer.

Authors:  Jie Cui; Biao Duan; Xuyang Zhao; Yan Chen; Shixun Sun; Wenjie Deng; Yujie Zhang; Jun Du; Yongchang Chen; Luo Gu
Journal:  Tumour Biol       Date:  2016-07-27

7.  Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.

Authors:  Daniel R Carter; Selina K Sutton; Marina Pajic; Jayne Murray; Eric O Sekyere; Jamie Fletcher; Anneleen Beckers; Katleen De Preter; Frank Speleman; Rani E George; Michelle Haber; Murray D Norris; Belamy B Cheung; Glenn M Marshall
Journal:  Mol Oncol       Date:  2016-03-02       Impact factor: 6.603

Review 8.  mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.

Authors:  Kenta Masui; Noriyuki Shibata; Webster K Cavenee; Paul S Mischel
Journal:  Bioessays       Date:  2016-07-18       Impact factor: 4.345

9.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.

Authors:  Xiaoyong Fu; Resel Pereira; Carmine De Angelis; Jamunarani Veeraraghavan; Sarmistha Nanda; Lanfang Qin; Maria L Cataldo; Vidyalakshmi Sethunath; Sepideh Mehravaran; Carolina Gutierrez; Gary C Chamness; Qin Feng; Bert W O'Malley; Pier Selenica; Britta Weigelt; Jorge S Reis-Filho; Ofir Cohen; Nikhil Wagle; Agostina Nardone; Rinath Jeselsohn; Myles Brown; Mothaffar F Rimawi; C Kent Osborne; Rachel Schiff
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-11       Impact factor: 11.205

10.  Maintaining multipotent trunk neural crest stem cells as self-renewing crestospheres.

Authors:  Sofie Mohlin; Ezgi Kunttas; Camilla U Persson; Reem Abdel-Haq; Aldo Castillo; Christina Murko; Marianne E Bronner; Laura Kerosuo
Journal:  Dev Biol       Date:  2019-01-18       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.